Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jchf.2020.05.005 http://scihub22266oqcxt.onion/10.1016/j.jchf.2020.05.005 32641226!7286640!32641226     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       JACC+Heart+Fail 2020 ; 8 (10): 789-799 Nephropedia Template TP {{tp|p=32641226|t=2020. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial |pdf=|usr=}}{{32641226}} gab.com Text Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial JO: JACC Heart Fail http://www.kidney.de/pget.php?&tw=1&pmid=32641226 #FOAvip The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial reported that sacubitril/valsartan (S/V), an angiotensin receptor-neprilysin inhibitor, significantly reduced mortality and heart failure (HF) hospitalization in HF patients with a reduced ejection fraction (HFrEF). However, fewer than 1% of patients in the PARADIGM-HF study had New York Heart Association (NYHA) functional class IV symptoms. Accordingly, data that informed the use of S/V among patients with advanced HF were limited. The LIFE (LCZ696 in Hospitalized Advanced Heart Failure) study was a 24-week prospective, multicenter, double-blinded, double-dummy, active comparator trial that compared the safety, efficacy, and tolerability of S/V with those of valsartan in patients with advanced HFrEF. The trial planned to randomize 400 patients >/=18 years of age with advanced HF, defined as an EF </=35%, New York Heart Association functional class IV symptoms, elevated natriuretic peptide concentration (B-type natriuretic peptide [BNP] >/=250 pg/ml or N-terminal pro-B-type natriuretic peptide [NT-proBNP] >/=800 pg/ml), and >/=1 objective finding of advanced HF. Following a 3- to 7-day open label run-in period with S/V (24 mg/26 mg twice daily), patients were randomized 1:1 to S/V titrated to 97 mg/103 mg twice daily versus 160 mg of V twice daily. The primary endpoint was the proportional change from baseline in the area under the curve for NT-proBNP levels measured through week 24. Secondary and tertiary endpoints included clinical outcomes and safety and tolerability. Because of the COVID-19 pandemic, enrollment in the LIFE trial was stopped prematurely to ensure patient safety and data integrity. The primary analysis consists of the first 335 randomized patients whose clinical follow-up examination results were not severely impacted by COVID-19. (Entresto [LCZ696] in Advanced Heart Failure [LIFE STUDY] [HFN-LIFE]; NCT02816736). Twit Text FOAVip Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial ????JACC Heart Fail http://www.kidney.de/pget.php?&tw=1&pmid=32641226 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32641226 #FOAvip English Wikipedia <ref>{{Cite pmid|32641226}}</ref> Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial #MMPMID32641226 Mann DL; Greene SJ; Givertz MM; Vader JM; Starling RC; Ambrosy AP; Shah P; McNulty SE; Mahr C; Gupta D; Redfield MM; Lala A; Lewis GD; Mohammed SF; Gilotra NA; DeVore AD; Gorodeski EZ; Desvigne-Nickens P; Hernandez AF; Braunwald E JACC Heart Fail 2020[Oct]; 8 (10): 789-799 PMID32641226show ga The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial reported that sacubitril/valsartan (S/V), an angiotensin receptor-neprilysin inhibitor, significantly reduced mortality and heart failure (HF) hospitalization in HF patients with a reduced ejection fraction (HFrEF). However, fewer than 1% of patients in the PARADIGM-HF study had New York Heart Association (NYHA) functional class IV symptoms. Accordingly, data that informed the use of S/V among patients with advanced HF were limited. The LIFE (LCZ696 in Hospitalized Advanced Heart Failure) study was a 24-week prospective, multicenter, double-blinded, double-dummy, active comparator trial that compared the safety, efficacy, and tolerability of S/V with those of valsartan in patients with advanced HFrEF. The trial planned to randomize 400 patients >/=18 years of age with advanced HF, defined as an EF /=250 pg/ml or N-terminal pro-B-type natriuretic peptide [NT-proBNP] >/=800 pg/ml), and >/=1 objective finding of advanced HF. Following a 3- to 7-day open label run-in period with S/V (24 mg/26 mg twice daily), patients were randomized 1:1 to S/V titrated to 97 mg/103 mg twice daily versus 160 mg of V twice daily. The primary endpoint was the proportional change from baseline in the area under the curve for NT-proBNP levels measured through week 24. Secondary and tertiary endpoints included clinical outcomes and safety and tolerability. Because of the COVID-19 pandemic, enrollment in the LIFE trial was stopped prematurely to ensure patient safety and data integrity. The primary analysis consists of the first 335 randomized patients whose clinical follow-up examination results were not severely impacted by COVID-19. (Entresto [LCZ696] in Advanced Heart Failure [LIFE STUDY] [HFN-LIFE]; NCT02816736). |*Aminobutyrates/therapeutic use[MESH] |*Angiotensin Receptor Antagonists/therapeutic use[MESH] |*Heart Failure/drug therapy/metabolism/physiopathology[MESH] |*Tetrazoles/therapeutic use[MESH] |Betacoronavirus[MESH] |Biphenyl Compounds[MESH] |COVID-19[MESH] |Cardiotonic Agents/therapeutic use[MESH] |Coronavirus Infections[MESH] |Dose-Response Relationship, Drug[MESH] |Double-Blind Method[MESH] |Drug Combinations[MESH] |Early Termination of Clinical Trials[MESH] |Glomerular Filtration Rate[MESH] |Heart Transplantation[MESH] |Heart-Assist Devices[MESH] |Hospitalization/statistics & numerical data[MESH] |Humans[MESH] |Hypotension/chemically induced[MESH] |Multicenter Studies as Topic[MESH] |Natriuretic Peptide, Brain/metabolism[MESH] |Pandemics[MESH] |Peptide Fragments/metabolism[MESH] |Pneumonia, Viral[MESH] |Randomized Controlled Trials as Topic[MESH] |SARS-CoV-2[MESH] |Stroke Volume[MESH]Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection F(epmc).pdf DeepDyve Pubget Overpricing